(36 days)
Not Found
No
The device description and performance studies focus on the chemical properties and stability of a glucose control solution, with no mention of AI or ML technologies.
No
The device is described as a "control solution" for testing the performance of a blood glucose monitoring system, not for treating a condition. Its intended use is "for in vitro diagnostic use."
Yes.
The "Intended Use / Indications for Use" section explicitly states "For in vitro diagnostic use".
No
The device description clearly states it is a "viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose," which is a physical substance, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Explicitly stated in the Intended Use: The very first line of the "Intended Use / Indications for Use" section clearly states "For in vitro diagnostic use".
- Purpose of the device: The device is a control solution used to assess the performance of a blood glucose monitoring system. This is a classic example of an IVD, as it's used outside the body to evaluate the accuracy of a diagnostic test.
N/A
Intended Use / Indications for Use
The SMS Glucose Control is intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of TheraSense FreeStyle Blood Glucose Monitor.
Product codes
75 JJX
Device Description
The SMS Glucose Control consists of a viscosity-adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals and in the home by people with diabetes mellitus
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Tests were performed to verify specific performance characteristics:
- Stability
- Open Vial
- Microbial Stress Stability
- Test precision
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
5. 510(k) Summary
JUN 28 2007
- Introduction: According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
- Specialty Medical Supplies (SMS) Submitter: 3882 NW 124th Avenue Coral Springs, FL 33065
- Contact Person: John C. Gormley American Biological Technologies, Inc. 940 Crossroads Blvd Seguin, TX 78155 (830) 372-1391 ex. 210 Establishment Registration Number: 1643621
Device Name:
Common Name:
Classification Name: Quality Control Material (assayed and unassayed).
SMS Glucose Control
and Unassayed)
Class I per 21 CFR 862.1660 Classification:
Name:
Manufacturer:
510(k) No.:
Product Code: 75 JJX
Chemistry
Predicate Devices:
Panel:
TheraSense FreeStyle Control TheraSense, Inc. K031260
Name: Liberty Glucose Control Manufacturer: Liberty Healthcare Group, Inc. 510(k) No.: K060481
Single Analyte Control Solution, All Types (Assayed
1
The SMS Glucose Control consists of a viscosity-Device Description: adjusted, aqueous liquid control solution containing a known quantity of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
- The SMS Glucose Control is intended for in vitro Intended Use: diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of TheraSense FreeStyle Blood Glucose Monitor.
Comparison to Predicate Device:
| Characteristic/
Aspect | Predicate Device No. 1 | Predicate Device No. 2 | New Product |
---|---|---|---|
Name | TheraSense FreeStyle | ||
Control | Liberty Glucose Control | SMS Glucose Control | |
510(k), Date | K031260, 12/19/2003 | K060481, 03/09/2006 | |
Number of | |||
Levels | 1 | 1 | 1 |
Analyte | Glucose | Glucose | Glucose |
Container | Plastic bottle with | ||
dropper-tip | Plastic bottle with dropper | ||
tip | Plastic bottle with | ||
dropper tip | |||
Fill Volume | 4.0 mL | 3.6 mL | 3.6 mL |
Color | Red | Red | Red |
Matrix | Buffered aqueous | ||
solution of D-Glucose, | |||
viscosity modifier, | |||
preservatives, and other | |||
non-reactive ingredients | Buffered aqueous | ||
solution of D-Glucose, a | |||
viscosity modifier, | |||
preservatives, and other | |||
non-reactive ingredients | Identical to Predicate | ||
Device No. 2 | |||
Indications for | |||
Use | To use with FreeStyle | ||
Blood Glucose | |||
Monitoring System for | |||
quality control purposes | |||
to verify that the | |||
FreeStyle Meter and | |||
Test Strips are working | |||
right. | Used to check the | ||
performance of FreeStyle | |||
Blood Glucose Systems. | Used to check the | ||
performance of | |||
FreeStyle Blood | |||
Glucose Systems. | |||
Target | |||
Population | Professional and home | ||
use | Professional and home | ||
use | Professional and | ||
home use |
2
· ····· · ···· · ···· ··
Tests were performed to verify specific performance Performance Studies: characteristics:
-
- Stability
-
- Open Vial
-
- Microbial Stress Stability
-
- Test precision
Comparison of the performance characteristics, Conclusion: formulation and intended use support the claim of substantial equivalence.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three lines forming its body and head. The eagle faces to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Specialty Medical Supplies c/o Mr. John C. Gormley American Biological Technologies, Inc. 940 Crossroads Blvd. Seguin, TX 78155
JUN 2 8 2007
Re: K071433
Trade/Device Name: Specialty Medical Supplies (SMS) Glucose Control Regulation Number: 21 CFR§862.1660 Regulation Name: Quality control material (assayed and unassayed). Regulatory Class: Class I, reserved Product Code: JJX Dated: May 22, 2007 Received: May 23, 2007
Dear Mr. Gormley:
We have reviewed your Section 510(k) premarket notification of intent to market the device w o nove rollowed your be determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for ass surver in May 28, 1976, the enactment date of the Medical Device Amendments, or to connineroo pror to May 2011 - 11:14 provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). and Coometer For (110) was the device, subject to the general controls provisions of the Act. The I ou may, aron's provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean 1 loase of actious that I Drivinsion that your device complies with other requirements of the Act that I Drinatal statutes and regulations administered by other Federal agencies. You must or any I ocoral station and including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
4
Page 2 -
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours.
Jean M. Cooper, M.S., D.V.M.
Jean M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number: 长 071433
SMS Glucose Control Device Name:
Indications For Use:
For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TheraSense FreeStyle Blood Glucose System.
Prescription Use (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use X (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
C
Division Sign-Off
510(k)
Office of In Vitro Diagnostic Device Evaluation and Safety
Page 1 of